Clinical Trials Logo

Abdominal Obesity clinical trials

View clinical trials related to Abdominal Obesity.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06376955 Not yet recruiting - Diabetes Clinical Trials

High Intensity Interval Versus Focused Ultrasound on Insulin Resistance in Diabetics With Abdominal Obesity

diabetic
Start date: April 16, 2024
Phase: N/A
Study type: Interventional

Obesity and diabetes share a common insulin resistance pathway and contribute to chronic hyperglycemia. Both high-intensity interval exercise (HIIE) and focused ultrasound (FUS) have been explored in the context of managing insulin resistance in diabetic individuals with abdominal obesity, though they operate through different mechanisms and have different implications.

NCT ID: NCT06355544 Not yet recruiting - Healthy Clinical Trials

Individual Factors Related to Chronic Low-grade Inflammation and Cardiometabolic Disease Risk

PINEAPPL
Start date: April 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about low-grade inflammation in healthy individuals and individuals with overweight or obesity. The main questions it aims to answer are: - Whether it is possible to predict low-grade inflammation - What are the medical, biological, and lifestyle variables related to low-grade inflammation? Participants will be asked to: 1. Attend a general medical visit to collect vital signs, anthropometric measurements, and collect blood samples. 2. Complete questionnaires and collect a stool sample at home.

NCT ID: NCT06208163 Not yet recruiting - Abdominal Obesity Clinical Trials

The Effects of Chiropractic in a Population With High Central Adiposity

OBE
Start date: February 15, 2024
Phase: N/A
Study type: Interventional

Since 1980, the global prevalence of obesity, commonly defined as a body mass index (BMI) of 30 or higher, has doubled. Importantly, high levels of central adiposity (i.e., abdominal fat) is associated with numerous PNI-related sequelae, including increased levels of psychological distress, cognitive deficits, ANS dysfunction, and immune marker abnormalities. To our knowledge, rigorous investigation of chiropractic's impact on psychoneuroimmunological (PNI)-related outcomes in people with high central adiposity is lacking. Based on limited evidence to date, it is plausible that clinically important PNI-related dysfunctions (e.g., heightened stress levels, executive function impairments, dysautonomia, immune dysregulation) common in this population could be ameliorated via chiropractic care.

NCT ID: NCT05882149 Not yet recruiting - Abdominal Obesity Clinical Trials

Single Strain Probiotic

CHOICE
Start date: July 15, 2023
Phase: N/A
Study type: Interventional

Probiotics have been recognized as functional foods with beneficial effects against obesity and cardiometabolic diseases, such as dyslipidemia, type 2 diabetes and the reduction of visceral fat mass, body weight and waist circumference. In previous studies, it was shown that capsule/powder probiotic or postbiotic supplementation containing a single strain probiotic, could reduce anthropometric parameters, including the visceral fat area, and contribute to type 2 diabetes management in subjects with abdominal obesity. Similar findings were found when this single strain probiotic was delivered through enriched seafood sticks. Results showed that enriched seafood sticks significantly reduced insulin concentrations and HOMA-IR, pulse pressure, waist circumference, body weight and triglycerides. These findings suggest that this specific single strain probiotic as a probiotic or postbiotic, could be a complementary strategy in the management of cardiometabolic disease risk factors. Probiotics have mostly been studied incorporated in dairy food matrix. Other food matrices, such as chewing gum, have scarcely been exploited by the food industry. Chewing gum as a novel vehicle for probiotics presents the ability to release active ingredients into the oral cavity with a steady and rapid action. Furthermore, it has a high acceptance amongst adults and children and present few side effects. No previous randomized controlled trials have examined the effect of a probiotic chewing gum on anthropometric adiposity biomarkers and glucose homeostasis in abdominally obese individuals. The main objective of the present study is to evaluate the efficacy of single strain probiotic in the reduction of waist circumference in abdominally obese individuals. The specific objectives: - To evaluate the efficacy of single strain probiotic in the improvement of other anthropometric biomarkers (waist-hip-ratio, body weight, BMI, total fat mass, visceral fat index, free fat mass, lean body mass, conicity index, visceral adipose tissue and subcutaneous fat). - To evaluate the efficacy of single strain probiotic in the management of glucose homeostasis. - To evaluate the efficacy of single strain probiotic in the management of serum lipid levels. - To evaluate the efficacy of single strain probiotic in the reduction of blood pressure and pulse pressure. - To asses Quality of life after single strain probiotic supplementation. - To identify changes in caloric intake and subjective satiety after single strain probiotic supplementation. - To identify changes in gastrointestinal health after single strain probiotic supplementation. - To identify changes in the oral microbiome after single strain probiotic supplementation. - To identify changes in the gastrointestinal microbiome after single strain probiotic supplementation.

NCT ID: NCT05749874 Not yet recruiting - Hypertension Clinical Trials

Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

ABCD
Start date: April 1, 2023
Phase: Phase 4
Study type: Interventional

This multicenter, double-blinded, randomized controlled trial aims to evaluate the effect of berberine on preventing cardiovascular disease and diabetes mellitus among individuals with high cardiometabolic risk in China.